<DOC>
	<DOCNO>NCT01678573</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( drug concentration change time ) abiraterone acetate oral administration abiraterone acetate different dose level 250 , 500 , 1000 mg healthy Chinese male participant fast condition .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics Abiraterone Healthy Chinese Male Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , randomize ( treatment sequence assign chance ) , 3-way crossover study ( method use switch participant one dose level another clinical study ) single dose abiraterone acetate healthy Chinese male participant . The study consist 3 phase : screening , open-label treatment , follow phase . After screen , randomly assign participant receive different dose level abiraterone acetate ( Treatment A = 250 mg ; Treatment B = 500 mg ; Treatment C = 1000 mg ) Day 1 3 treatment period accord randomized schedule fast condition ( Sequence 1 = ABC ; Sequence 2 = BAC ; Sequence 3 = CBA ) . Each treatment period separate washout period ( period participant receive study medication ) least 7 day . In follow-up phase , study-related adverse event monitor investigator . Serial blood sample pharmacokinetic analysis collect safety monitor throughout study . The total study duration approximately 42 day .</detailed_description>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Body mass index within 18 27 kg/m2 ( inclusive ) body weight 50 kg screening Protocoldefined laboratory electrocardiogram parameter Negative test result select medication substance abuse negative exhale carbon monoxide test checkin day period Agrees protocoldefined use effective contraception Willing confine clinical research facility time period specify protocol Significant history current manifestation significant metabolic , allergic , dermatological , hepatic , renal , hematologic , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder History hypersensitivity reaction study medication relate compound excipients use formulation Confirmed hepatitis A , B , C infection human immunodeficiency virus ( HIV ) 1 HIV2 infection screen Serum testosterone level &lt; 200 ng/dL Use tobacco nicotinecontaining product Known suspect use illicit drug last year Protocol contraindicate medications/preparations ( prescription nonprescription )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>Abiraterone</keyword>
	<keyword>JNJ-212082</keyword>
	<keyword>Zytiga</keyword>
	<keyword>Chinese</keyword>
	<keyword>Fasted</keyword>
</DOC>